- Home
- TGTX vs TRNO Comparison
TGTX vs TRNO Comparison
Compare TGTX & TRNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGTX
- TRNO
- Stock Information
- Founded
- TGTX 1993
- TRNO 2009
- Country
- TGTX United States
- TRNO United States
- Employees
- TGTX N/A
- TRNO N/A
- Industry
- TGTX Biotechnology: Pharmaceutical Preparations
- TRNO Real Estate
- Sector
- TGTX Health Care
- TRNO Finance
- Exchange
- TGTX Nasdaq
- TRNO Nasdaq
- Market Cap
- TGTX 5.1B
- TRNO 6.0B
- IPO Year
- TGTX 1995
- TRNO 2010
- Fundamental
- Price
- TGTX $36.73
- TRNO $57.98
- Analyst Decision
- TGTX Strong Buy
- TRNO Buy
- Analyst Count
- TGTX 6
- TRNO 10
- Target Price
- TGTX $47.50
- TRNO $65.00
- AVG Volume (30 Days)
- TGTX 1.9M
- TRNO 654.2K
- Earning Date
- TGTX 11-03-2025
- TRNO 11-05-2025
- Dividend Yield
- TGTX N/A
- TRNO 3.56%
- EPS Growth
- TGTX N/A
- TRNO 40.84
- EPS
- TGTX 0.36
- TRNO 2.52
- Revenue
- TGTX $454,069,000.00
- TRNO $425,998,000.00
- Revenue This Year
- TGTX $82.22
- TRNO $21.56
- Revenue Next Year
- TGTX $47.76
- TRNO $10.82
- P/E Ratio
- TGTX $101.18
- TRNO $23.14
- Revenue Growth
- TGTX 30.96
- TRNO 22.17
- 52 Week Low
- TGTX $21.16
- TRNO $48.18
- 52 Week High
- TGTX $46.48
- TRNO $69.20
- Technical
- Relative Strength Index (RSI)
- TGTX 72.14
- TRNO 54.76
- Support Level
- TGTX $34.52
- TRNO $57.78
- Resistance Level
- TGTX $37.45
- TRNO $59.00
- Average True Range (ATR)
- TGTX 1.10
- TRNO 1.04
- MACD
- TGTX 0.59
- TRNO -0.03
- Stochastic Oscillator
- TGTX 90.30
- TRNO 53.78
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
About TRNO Terreno Realty Corporation
Terreno Realty Corp is a real estate investment trust engaged in acquiring, owning, and operating industrial real estate in six coastal U.S. markets: Los Angeles, Northern New Jersey/New York City, San Francisco Bay Area, Seattle, Miami, and Washington, D.C. The company invests in several types of industrial real estate, including warehouse/distribution, flex (including light industrial and research and development), transshipment, and improved land.